Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Neurotype Inc
Profile last edited on: 10/27/21      CAGE: 8DPW2      UEI: CKJEWEVBWP54

Business Identifier: Decoding brain signals to improve healthcare for addictions and mental disorders
Year Founded
2019
First Award
2020
Latest Award
2021
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2310 Aldrich Avenue South Unit 210
Minneapolis, MN 55405
   (651) 431-0574
   N/A
   N/A
Location: Single
Congr. District: 05
County: Hennepin

Public Profile

Neurotype Inc. is an early stage small firm structured around developing digital health technologies that interact with brain and body sensors to improve mental and behavioral healthcare. Principals of the firm are addressing the develpment of diagnostic and neuro-feedback tools designed to manage care in opioid use disorder and other addiction settings - building portable brain sensing tools to support the recovery of those struggling with Substance Use Disorders.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$235,084
Phase II Dollars
$169,827
Total Awarded
$404,911

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2021 2 NIH $404,911
Project Title: Mobile Brain Sensing Platform for Detection of Opioid Craving and Treatment Response
0 1 NIH $328,963
Project Title: Cue-induced drug craving monitoring for opioid use disorder with visual evoked potentials
0 1 NIH $326,672
Project Title: Closed-loop attention bias modification brain training for opioid use disorder

Key People / Management

  Scott Burwell -- CEO and Co-Founder

  Justin Anke

Company News

There are no news available.